Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THVD-102 for primary focal hyperhidrosis
ACTRN12615000873527Phase 2Active, not recruiting
- Sponsor
- TheraVida, Inc.
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RVT-504, oxybutynin and pilocarpine in Primary hyperhidrosis (PH) (3 arms), sponsored by TheraVida, Inc. Primary endpoints: Safety of THVD-102 and Efficacy of THVD-102 in reducing hyperhidrosis. Started Apr 2015; status: active, not recruiting.
02
Drugs
RVT-504oxybutyninpilocarpine
03
Conditions
Primary hyperhidrosis (PH)
Beyond the preview
Go deeper on ACTRN12615000873527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000873527.